Related Experiment Video
Updated: Oct 13, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Dibenzofuran Derivatives Inspired from Cercosporamide as Dual Inhibitors of Pim and CLK1 Kinases
Viet Hung Dao1, Isabelle Ourliac-Garnier1, Cédric Logé1
1Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, Université de Nantes, 44000 Nantes, France.
Abstract:
Pim kinases (proviral integration site for Moloney murine leukemia virus kinases) are overexpressed in various types of hematological malignancies and solid carcinomas, and promote cell proliferation and survival. Thus, Pim kinases are validated as targets for antitumor therapy. In this context, our combined efforts in natural product-inspired library generation and screening furnished very promising dibenzo[b,d]furan derivatives derived from cercosporamide. Among them, lead compound 44 was highlighted as a potent Pim-1/2 kinases inhibitor with an additional nanomolar IC50 value against CLK1 (cdc2-like kinases 1) and displayed a low micromolar anticancer potency towards the MV4-11 (AML) cell line, expressing high endogenous levels of Pim-1/2 kinases. The design, synthesis, structure-activity relationship, and docking studies are reported herein and supported by enzyme, cellular assays, and Galleria mellonella larvae testing for acute toxicity.
Insights
Researchers developed novel dibenzofuran compounds that inhibit Pim kinases, crucial targets in cancer therapy. Lead compound 44 shows potent anticancer activity against AML cells and low toxicity, offering a promising new therapeutic avenue.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Pim kinases are overexpressed in various cancers, promoting cell proliferation and survival, making them validated targets for antitumor therapy.
- Natural product-inspired drug discovery offers a promising avenue for identifying novel anticancer agents.
Purpose of the Study:
- To design, synthesize, and evaluate novel dibenzofuran derivatives as potent Pim kinase inhibitors.
- To investigate the anticancer activity and toxicity profile of lead compound 44.
Main Methods:
- Synthesis of dibenzofuran derivatives inspired by natural products.
- Enzyme inhibition assays to determine IC50 values for Pim-1/2 and CLK1 kinases.
- Cellular assays using MV4-11 (AML) cell line to assess anticancer potency.
- Acute toxicity testing in Galleria mellonella larvae.
Main Results:
- Lead compound 44, a dibenzofuran derivative, demonstrated potent inhibition of Pim-1/2 kinases with nanomolar IC50 values.
- Compound 44 also inhibited CLK1 (cdc2-like kinases 1) with nanomolar potency.
- Anticancer activity was observed in the MV4-11 AML cell line with low micromolar potency.
- Compound 44 exhibited low acute toxicity in Galleria mellonella larvae.
Conclusions:
- Novel dibenzofuran derivatives, exemplified by compound 44, are potent inhibitors of Pim kinases and exhibit promising anticancer activity.
- Compound 44 represents a potential lead for developing new therapies against hematological malignancies and solid carcinomas.
- The natural product-inspired approach is effective for discovering novel kinase inhibitors with favorable toxicity profiles.
Related Concept Videos
Inhibition of Cdk Activity
Drugs that Destabilize Microtubules

